This review presents a robust strategy to design photosensitizers (PSs) for various species. Photodynamic therapy (PDT) is a photochemical-based treatment approach that involves the use of light combined with a light-activated chemical, referred to as a PS. Attractively, PDT is one of the alternatives to conventional cancer treatment due to its noninvasive nature, high cure rates, and low side effects. PSs play an important factor in photoinduced reactive oxygen species (ROS) generation. Although the concept of photosensitizer-based photodynamic therapy has been widely adopted for clinical trials and bioimaging, until now, to our surprise, there has been no relevant review article on rational designs of organic PSs for PDT. Furthermore, most of published review articles in PDT focused on nanomaterials and nanotechnology based on traditional PSs. Therefore, this review aimed at reporting recent strategies to develop innovative organic photosensitizers for enhanced photodynamic therapy, with each example described in detail instead of providing only a general overview, as is typically done in previous reviews of PDT, to provide intuitive, vivid, and specific insights to the readers.
To date, a large number of photosensitizers (PS) have introduced heavy atoms to improve the ISC process and 1O2 generation. However, they often show low efficiency in hypoxic conditions, aggregate states, and turn-off PDT in the dark. Besides that, the toxicity of heavy metals is also concerned. Therefore, we developed lysosome-targeted heavy-metal-free PS (3S and 4S) based on thionated naphthalimide for hypoxic cancer photodynamic therapy (PDT), not only under white light but also in the dark via thermal-induced 1O2 generation. AIEgen (3O and 4O) were prepared for studying the PDT action of PSs (3S and 4S) in lysosome and aggregate state. We also examined the photophysical properties of AIEgen (3O and 4O) and PS (3S and 4S) by UV–vis absorption, fluorescent emission spectra, and theoretical calculations.
The ability to detect hypochlorite (HOCl/ClO−) in vivo is of great importance to identify and visualize infection. Here, we report the use of imidazoline-2-thione (R1SR2) probes, which act to both sense ClO− and kill bacteria. The N2C=S moieties can recognize ClO− among various typical reactive oxygen species (ROS) and turn into imidazolium moieties (R1IR2) via desulfurization. This was observed through UV–vis absorption and fluorescence emission spectroscopy, with a high fluorescence emission quantum yield (ՓF = 43–99%) and large Stokes shift (∆v∼115 nm). Furthermore, the DIM probe, which was prepared by treating the DSM probe with ClO−, also displayed antibacterial efficacy toward not only Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) but also methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum ß-lactamase–producing Escherichia coli (ESBL-EC), that is, antibiotic-resistant bacteria. These results suggest that the DSM probe has great potential to carry out the dual roles of a fluorogenic probe and killer of bacteria.
Three novel pyrazine-based organic photosensitizers denoted as TPP, TPPS, and TPPF were synthesized for dye-sensitized solar cell (DSSC) studies. Chemical structures of the pyrazine-based photosensitizers were designed with pyrazine derivatives as acceptors, triphenylamine groups as donors, and the thiophene–cyanoacryl group as an auxiliary heterocyclic linkers-acceptor. Using UV-vis spectrophotometry, cyclic voltammetry, and density functional theory calculations, optical and electrochemical characteristics of these pyrazine-based photosensitizers were examined and explored in relation to photovoltaic parameters. The effects of the molecular structures of these photosensitizers on the performances of DSSCs were also investigated. The overall conversion efficiencies of DSSCs based on pyrazine-based photosensitizers were 1.31~2.64% under AM 1.5 irradiation of 100 mW/cm2. To confirm the effect of interfacial charge transfer on photovoltaic performances of DSSC based on pyrazine-based photosensitizers, interfacial charge transfer resistances were investigated by electrical impedance spectroscopy (EIS) measurements.
This article describes the preparation and analysis of Cd 2+-sensing polydiacetylene-based chemosensors (PDA-MP). Polydiacetylenes (PDAs), a family of conjugated polymers, exhibit a strong response to external stimuli. Accordingly, we have designed a novel PDA sensor, which is linked to mono 2-picolylamine, to increase the PCDA-MP monomer content in polymer system. As a result, it enhanced sensitivity toward Cd 2+ with the low detection limit (2.10 μM) in aqueous solution. Our sequential modification of chelate structure improved the Cd 2+-sensing ability of PDAs. Finally, the interaction between PCDA-MP and Cd 2+ was confirmed by Raman spectroscopy, Field Emission Scanning Electron Microscopes (FE-SEM), and Proton nuclear magnetic resonance (1 H NMR).
The development of a fluorogenic chemosensors with high sensitivity for copper ion (Cu2+) has been receiving great attention in recent years because of their potential application in clinical biochemistry and the environment studies. In the present study, we designed and synthesized a fluorescent probe, Np‐azaCE, with 1,8‐naphthalimides as a core structure and 1,4‐diaza‐9‐crown‐3‐ether as a copper ion tweeze, which showed selective and sensitive fluorometric change upon addition of a copper ion. The Np‐azaCE chemosensor was highly selective for Cu2+ over the other metal ions with fluorescent quenching. Finally, the Cu2+ detection limit and job's plot of Np‐azaCE were calculated using UV–visible spectrophotometer and fluorescence spectrophotometer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.